We showed that trastuzumab binds to breast cancer cells at varying levels, depending on the HER2 expression levels and density on the cell membrane of MCF-7 (ER +), SKBR3 (HER2 +), and KPL-4 (HER2 +) cells. Here, ERBB2 is linked to breast cancer.